Lexaria Bioscience (LEXX) Equity Ratio (2011 - 2026)

Lexaria Bioscience has disclosed Equity Ratio across 16 years of filings, most recently posting 1.02 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 1.02, up 30.63% year-over-year; the trailing twelve-month figure through Feb 2026 was 1.02 (up 30.63% YoY), and the FY2025 annual result was 0.72, down 17.09% from the prior year.
• Equity Ratio came in at 1.02 for Q1 2026 at Lexaria Bioscience, up from 0.75 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 96.71 in Q1 2024 to a low of 0.72 in Q3 2025.
• The 5-year median for Equity Ratio is 0.98 (2022), against an average of 14.46.
• Across the five-year window, Equity Ratio surged 6019.55% in 2023 and plunged 99.19% in 2025, its largest moves.
• Lexaria Bioscience's Equity Ratio stood at 50.23 in 2022, then sank by 49.37% to 25.43 in 2023, then sank by 96.23% to 0.96 in 2024, then declined by 22.06% to 0.75 in 2025, then surged by 36.14% to 1.02 in 2026.
• The last three Equity Ratio figures came in at 1.02 (Q1 2026), 0.75 (Q4 2025), and 0.72 (Q3 2025), per Business Quant data.